Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating melanoma and a pharmaceutical composition comprising chlorogenic acid and used for treating melanoma.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating lupus erythematosus. The chlorogenic acid can improve an immunity function. The present invention provides a preparation for treating lupus erythematosus, comprising chlorogenic acid and pharmaceutically acceptable auxiliary materials. The present invention further provides a combined medicine comprising chlorogenic acid and medicines for treating lupus erythematosus.

Abstract: A method and apparatus to provide hop-by-hop tracking for a communication network is described. In one embodiment, each router verifies that a next downstream router supports tracking and in response, adds a tracking indicator and a timestamp to the data packet. An end router provides a compilation of all the timestamps back to the originating router.

Abstract: A method and apparatus to provide hop-by-hop tracking for a communication network is described. In one embodiment, each router verifies that a next downstream router supports tracking and in response, adds a tracking indicator and a timestamp to the data packet. An end router provides a compilation of all the timestamps back to the originating router.

Abstract: The present invention relates to phosphoric acid/phosphonic acid derivatives shown by formula (I), wherein, R1 or R2 represents the following structures: (Q1), or (Q2), or (Q3). Q1 represents ester derivatives of L-amino acid, wherein R3 is alkyl with 1-6 carbon atoms or cycloalkyl, R4 is H or alkyl with 1-6 carbon atoms; Q2 represents hydroxyl substituted benzodioxane derivatives; Q3 represents hydroxyl substituted benzodioxolane derivatives; R1 or R2 is the same or different, but at least one of them is Q2 or Q3; D represents residues of pharmacologically active molecules containing a phosphate/phosphonate group, i.e. formula (II) represents pharmacologically active molecules containing a phosphate/phosphonate group; and when R1 and R2 are different, the configuration of the P atom connected to R1 and R2 is of R or S type.

Abstract: A method and apparatus to provide hop-by-hop tracking for a communication network is described. In one embodiment, a router verifies that a next downstream router does not support tracking and in response terminates hop-by-hop tracking. An end router provides a compilation of all the timestamps back to the originating router.

Abstract: A circuit and a method are disclosed for adjusting a body bias voltage applied to a power gating switch. The circuit comprises: a first supply voltage (916), a body bias generator (918) formed from a plurality of series connected MOSFETs coupled to a second supply voltage (928) and an adaptive switch (910) providing an output coupled to either the first supply voltage or the body bias generator output (926), wherein the output of the adaptive switch is a first body bias voltage when coupled to the first supply voltage and is a second body bias voltage when coupled to the body bias generator output such that the first body bias voltage is greater than the second body bias voltage when configured as a gating header switch and the first body bias voltage is less than the second body bias voltage when configured as a gating footer switch.

Abstract: System and methods are provided for dynamic voltage control of a device. An example system includes: a power management unit configured to dynamically detect one or more operation modes of a plurality of chip components of a device, determine a target operating voltage based at least in part on the detected operation modes, and generate one or more voltage control signals associated with the target operating voltage; an input/output control unit configured to, in response to the one or more voltage control signals, toggle a plurality of input/output pins; and a power management integrated circuit connected to the plurality of input/output pins and configured to change an actual operating voltage of the device to the target operating voltage in response to the toggling of the plurality of input/output pins.

Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.

Abstract: This invention discloses that the five crystal forms of XLF-III-43 can be used as crude drugs. The invention also relates to the preparation methods of the five crystal forms of XLF-III-43 as crude drugs, to the applications of the sterling of the five crystal forms of XLF-III-43 and mixed crystals in different proportions as medicinally active components to develop various kinds of medicines and compound medicines. In addition, this invention also relates to applying the crystal samples of XLF-III-43 as crude drugs to treat kidney dysfunction, cardiocerebral vessel diseases, hypertension, type II diabetic mellitus, complications of hypertension and diabetic mellitus, tumor, precancerosis, edema, and achieves therapeutic effects by enhancing blood drug levels resulted from effects of crystal forms in the processes of treating all kinds of diseases.

Abstract: A method and apparatus to provide hop-by-hop tracking for a communication network is described. In one embodiment, a router verifies that a next downstream router does not support tracking and in response terminates hop-by-hop tracking. An end router provides a compilation of all the timestamps back to the originating router.

Abstract: A method and apparatus to provide hop-by-hop tracking for a communication network is described. In one embodiment, a router verifies that a next downstream router supports tracking and in response, adds a tracking indicator and a timestamp to the data packet. An end router provides a compilation of all the timestamps back to the originating router.

Abstract: The present invention relates to novel coumarin derivatives, their carboxamides, pharmaceutical compositions containing them and their uses as drugs for kidney protection, treating drugs of hypertension, cardio-cerebrovascular diseases, non-insulin dependent diabetes, tumor, pre-cancerous lesion, and edemas.

Abstract: The present invention relates to the salts of (+)-13a-(S)-deoxytylophorinine represented by the general formula (I), the preparation method thereof, the pharmaceutical compositions containing them, and their use as medicaments for prevention and/or treatment of cancer and/or inflammation disease.

Abstract: In one example embodiment, a system and method is provided that includes establishing a plurality of Pseudo Wire (PW) connections between a first network appliance region and a second network appliance region to transmit data from the first network appliance region to the second network appliance region along an active PW. Further, the method includes disabling the active PW when a failure of the active PW is detected. Additionally, the method may include selecting an inactive PW to become a new active PW such that the data may be transmitted from the first network appliance region to the second network appliance region. Moreover, the method includes switching from the active PW to the new active PW.

Abstract: This invention discloses that the five crystal forms of XLF-III-43 can be used as crude drugs. The invention also relates to the preparation methods of the five crystal forms of XLF-III-43 as crude drugs, to the applications of the sterling of the five crystal forms of XLF-III-43 and mixed crystals in different proportions as medicinally active components to develop various kinds of medicines and compound medicines. In addition, this invention also relates to applying the crystal samples of XLF-III-43 as crude drugs to treat kidney dysfunction, cardiocerebral vessel diseases, hypertension, type II diabetic mellitus, complications of hypertension and diabetic mellitus, tumor, precancerosis, edema, and achieves therapeutic effects by enhancing blood drug levels resulted from effects of crystal forms in the processes of treating all kinds of diseases.

Abstract: Rectifying method for color blindness and the production method of rectifying eyeglasses for color blindness by using a computer to simulate the process of rectifying color blindness, improving the basic color, the color tone, and color saturation of the light entering the eye. In the rectifying of the color blindness, there are numerous kinds of spectrums and parameters of the rectifying eyeglasses for color blindness, which are then grouped under four types. The rectifying eyeglasses for color blindness change the proportion of stimulus of the three kinds of optic cone cells on the retina and alter the color codes of the visional area of the cerebral cortex, thus when the color blind viewer wears the properly chosen eyeglasses, the ability to discriminate between colors is greatly improved.

Abstract: A method and apparatus to provide hop-by-hop tracking for a communication network is described. In one embodiment, a router verifies that a next downstream router supports tracking and in response, adds a tracking indicator and a timestamp to the data packet. An end router provides a compilation of all the timestamps back to the originating router.

Abstract: The present invention discloses cephalomannine derivatives of general formula (I), a process for preparation of such cephalomannine derivatives, a composition containing such compounds, and use of said compounds in the manufacture of a medicament for the treatment of tumors, especially multidrug resistant tumors.

Abstract: In one example embodiment, a system and method is provided that includes establishing a plurality of Pseudo Wire (PW) connections between a first network appliance region and a second network appliance region to transmit data from the first network appliance region to the second network appliance region along an active PW. Further, the method includes disabling the active PW when a failure of the active PW is detected. Additionally, the method may include selecting an inactive PW to become a new active PW such that the data may be transmitted from the first network appliance region to the second network appliance region. Moreover, the method includes switching from the active PW to the new active PW.